Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. Explore our real-world data analyses to support your strategic decisions.
Healthcare, like many areas of modern life, has been transformed by the internet and related digital technologies.
It is no surprise that innovation in the world of digital health is transforming the way healthcare is delivered.
New Avalere analysis evaluates the trends in baseline patient characteristics among Medicare fee-for-service beneficiaries with stand-alone Part D coverage who initiated a direct oral anticoagulant during the period 2013–2017.
As health plans evaluate more efficient ways to engage and retain members, they should focus on existing high-touch points to improve healthcare access and the overall experience. Augmenting these efforts can generate more evidence-based patient management thus improving overall health outcomes.
As technology comes to the forefront in healthcare innovation, the venture capital arms of many pharmaceutical companies are solidifying their presence as key investors.
Avalere experts recently presented their research, “Comparison of Healthcare Utilization Among Managed Medicaid Individuals Diagnosed with Multiple Sclerosis Treated with Emergent vs. Established Disease-Modifying Therapy in the US.”
In the coming months, Avalere experts will be presenting new data and research at major conferences, featuring insights derived from Inovalon’s Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry®).
Partnerships between traditional healthcare players and big technology companies seek to improve care delivery and patient outcomes in innovative ways.
Findings from a new Avalere study, titled “Prevalence and Likelihood of Hospital Admission and Readmission in Patients with Serious Mental Illness,” were presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific conference on Sunday, September 9, 2018.
Of the 329 oncology HTAs analyzed from the period 2013–2017, 29% resulted in positive recommendations without restrictions.
Tune in to episode 2 of our discussion covering why the FDA is so interested in real-world evidence and how they are approaching it.
Kenny Kan has joined the Avalere team leading the firm's actuarial analytics. Prior to joining Avalere, Kan served as the Chief Actuary at Humana and CareFirst.
Gillian Wollett, Senior Vice President of Avalere’s FDA & Regulatory Policy team, recently published “A ‘Global Reference’ Comparator for Biosimilar Development” in BioDrugs.
On Tuesday, June 13, Christie Teigland, PhD, will participate in a panel discussion entitled “Measuring and Reporting Social Risk Factors” as part of a dissemination meeting on the report series “Accounting for Social Risk Factors in Medicare Payment,” sponsored by the National Academies of Medicine.
Avalere experts examine the challenges and successful approaches to outcomes-based contracts.
Avalere experts say use of outcomes-based contracts could further goals to improve patient outcomes and manage drug costs
At the Asembia Specialty Pharmacy Summit 2017, an Avalere-led panel identified three focus areas for specialty pharmacies looking to achieve market leadership in an increasingly value-based care environment.
Avalere recently partnered with the National Pharmaceutical Council to examine payers' perspectives regarding the use of patient data and how it can be used to shape care delivery, improve system efficiencies, and achieve better health outcomes.
Avalere will empower expanded insight and improvement in outcomes for value-based diabetes medications, using Inovalon’s data resources and advanced value-based care platforms.
Earlier this year, Avalere led a work group of rheumatology, orthopedic surgery, psychiatry, sports medicine, and primary care clinicians to develop appropriate use criteria for the use of hyaluronic acid (HA) in the treatment of knee osteoarthritis (OA).